Abstract presented at the 11th Trends in Medical Mycology publicly available
Stockholm, Sweden - October 23, 2023 - Biosergen AB , a clinical-stage biotech company specializing in the development of innovative anti-fungal therapies, today announced that the company's abstract... The abstract presented at the 11th Trends in Medical Mycology conference, "Biosergen," or the "Company," a clinical-stage biotech company specializing in the development of innovative anti-fungal therapies, has been released publicly. The abstract, presented by COO, stated that single and multiple dose infusions of BSG005 were safe in healthy subjects and that single or multiple intravenous infusions were safe for healthy subjects. The presentation also highlighted the need for novel anti- fungal treatments. The title of the abstract is "First in human data on BSG003," a genetically engineered polyene macrolide evaluated in a double-blinded placebo-controlled Phase 1 trial. Currently, the company is preparing a Phase 2 clinical trial in which patients suffering from severe fungal infections will be tested for their potential as a new antifungal treatment.
Published : 2 years ago by MarketScreener in Finance
- - ("Biosergen" or the "Company"), a clinical-stage biotech company specializing in the development of innovative anti-fungal therapies, today announced that the company's abstract about the drug candidate BSG005, which was presented at the 11th Trends in Medical Mycology, on , is now publicly available
The abstract presentation, given by COO , laid out that single and multiple dose intravenous infusions of BSG005 were safe in healthy subjects. Adverse events were mild to moderate in severity, the majority of adverse events being infusion-related in the single ascending dose part of the trial and phlebitis in the multi ascending dose part of the trial, and no severe adverse events were seen in the study. Also, basic pharmacovigilance parameters were established.
COO, , who presented the data to the conference audience, stated, "The engaging discussions and insights shared during the conference further highlight the need for novel anti-fungal treatments. It was a pleasure to be able to contribute to this scientific conversation with our encouraging data on BSG005."
The title of the abstract is "First in human data on BSG005, a genetically engineered polyene macrolide evaluated in a double-blinded placebo-controlled Phase 1 trial" and is accessible on the conference website and attached to this release.
Currently, and its partner are preparing a Phase 2 clinical trial in . The trial will enrol patients suffering from severe fungal infections such as mucormycosis, aspergillosis, and candidiasis. Based on the safety and efficacy profile demonstrated in the preclinical studies and the phase I trials, as also published in the above-mentioned abstract, BSG005 may provide a suitable treatment option for these patients.
For further information about , please contact:
Dr. , CEO
Telephone: +45 2080 2470
E-mail: [email protected]
ABOUT
is a leading clinical-stage biotechnology company at the forefront of antifungal drug development. Our mission is to develop BSG005, our lead drug candidate, into the new first-line treatment choice for invasive fungal diseases, while generating significant returns for our shareholders. Our Phase I trial showcased the exceptional safety and tolerability of BSG005, especially when compared to existing alternatives. Building on those results we are now advancing to test the drug in patients expected to clinically validate BSG005's potential as a new and strong antifungal treatment. development of BSG005 is based on two decades of scientific work at the of Science and Technology. For more information, visit www.biosergen.net.
Topics: Markets